ATE309802T1 - Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen - Google Patents

Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen

Info

Publication number
ATE309802T1
ATE309802T1 AT03723620T AT03723620T ATE309802T1 AT E309802 T1 ATE309802 T1 AT E309802T1 AT 03723620 T AT03723620 T AT 03723620T AT 03723620 T AT03723620 T AT 03723620T AT E309802 T1 ATE309802 T1 AT E309802T1
Authority
AT
Austria
Prior art keywords
cyclopamine
corticosteroid
skin
lesions
treatment
Prior art date
Application number
AT03723620T
Other languages
English (en)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29247069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE309802(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/TR2002/000017 external-priority patent/WO2002078704A1/en
Application filed by Sinan Tas filed Critical Sinan Tas
Application granted granted Critical
Publication of ATE309802T1 publication Critical patent/ATE309802T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03723620T 2002-04-19 2003-03-17 Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen ATE309802T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/TR2002/000017 WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis
PCT/TR2003/000017 WO2003088964A1 (en) 2002-04-19 2003-03-17 Use of cyclopamine in the treatment of psoriasis and other skin disorders

Publications (1)

Publication Number Publication Date
ATE309802T1 true ATE309802T1 (de) 2005-12-15

Family

ID=29247069

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03723620T ATE309802T1 (de) 2002-04-19 2003-03-17 Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen

Country Status (15)

Country Link
US (6) US7605167B2 (de)
EP (2) EP1411938B1 (de)
JP (1) JP2006512281A (de)
KR (4) KR20080094739A (de)
CN (2) CN101642458A (de)
AT (1) ATE309802T1 (de)
AU (1) AU2003230541B2 (de)
BR (1) BR0309396A (de)
CA (3) CA2452152A1 (de)
DE (1) DE60302348T2 (de)
DK (1) DK1496895T3 (de)
EA (1) EA200401355A1 (de)
ES (1) ES2253672T3 (de)
MX (1) MXPA04010294A (de)
WO (1) WO2003088964A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
EP1235851B1 (de) 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP1561464A3 (de) * 2001-07-02 2007-04-25 Sinan Tas Verwendung des Cyclopamins zur Behandlung des basalen Zellkarzinoms und anderer Tumoren
US20170326118A1 (en) * 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
EP1411938B1 (de) * 2001-07-02 2005-07-06 Tas, Sinan Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
AU2005280112B2 (en) * 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
JP2008514726A (ja) * 2004-09-30 2008-05-08 ザ ユニヴァーシティー オヴ シカゴ ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
WO2007054623A2 (en) * 2005-11-11 2007-05-18 Licentia Oy Mammalian hedgehog signaling inhiabitors
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
US20110034498A1 (en) * 2006-03-24 2011-02-10 Mcgovern Karen J Dosing regimens for the treatment of cancer
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
RU2009137012A (ru) 2007-03-07 2011-04-20 Инфинити Дискавери, Инк. (Us) Аналоги циклопаминлактама и способы их применения
JP2010520295A (ja) * 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド へテロ環状シクロパミン類似体及びその使用方法
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
PE20091180A1 (es) * 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
CA2710858A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110135739A1 (en) * 2009-11-06 2011-06-09 Bennett Carter Oral Formulations of a Hedgehog Pathway Inhibitor
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
PL3302428T3 (pl) 2015-06-04 2026-04-13 Sol-Gel Technologies Ltd. Preparaty do zastosowania miejscowego do dostarczania związków inhibitora hedgehog i ich zastosowanie
EP3565520B1 (de) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
WO2020118095A1 (en) 2018-12-06 2020-06-11 OctoTech, Inc. Rf receiver architectures with parametric circuits
JP2024522808A (ja) * 2021-06-21 2024-06-21 パルヴェラ セラピューティクス、インク． ゴーリン症候群を治療するための方法および組成物
US20240384291A1 (en) 2021-09-13 2024-11-21 Sinan Tas Effective Interventions With Aging and Diseases Of Aging Of Human and Their Consequences

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT73772B (en) * 1980-10-06 1983-10-14 Glaxo Group Ltd Topically administrable pharmaceutical compositions containing anti-inflammatory steroids
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
DE69841320D1 (de) 1997-02-10 2010-01-07 Harvard College Verfahren zur modulation von hämatopoese und vaskulärem wachstum
US7741298B2 (en) 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US6238876B1 (en) 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US20050130922A1 (en) 1997-06-20 2005-06-16 Altaba Ariel R.I. Method and compositions for inhibiting tumorigenesis
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) * 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
US6867216B1 (en) * 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ATE283700T1 (de) * 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
US20050080138A1 (en) 1999-09-16 2005-04-14 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1235851B1 (de) * 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1646395B8 (de) * 1999-11-30 2014-12-17 Curis, Inc. Verfahren und zusammensetzungen zur regulierung der lymphozytenaktivität
US6951839B1 (en) * 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683108B1 (en) 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
AU7549501A (en) 2000-06-16 2002-01-02 Biogen Inc Angiogenesis-modulating compositions and uses
CU23175A1 (es) 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
US20040060568A1 (en) 2000-10-13 2004-04-01 Henryk Dudek Hedgehog antagonists, methods and uses related thereto
US20020165221A1 (en) * 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1401469A2 (de) 2001-04-09 2004-03-31 Lorantis Limited Therapeutische verwendung und identifikation von modulatoren des hedgehog-signalübertragungsweges oder eines seiner zielübertragungswege
EP1411938B1 (de) * 2001-07-02 2005-07-06 Tas, Sinan Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
EP1561464A3 (de) * 2001-07-02 2007-04-25 Sinan Tas Verwendung des Cyclopamins zur Behandlung des basalen Zellkarzinoms und anderer Tumoren
NZ532310A (en) * 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
US6927205B2 (en) * 2003-04-28 2005-08-09 Procyte Corporation Compositions and methods for treatment of psoriasis
KR20050037103A (ko) 2003-10-17 2005-04-21 주식회사 엘지생활건강 피부 미백용 화장료 조성물
AU2005280112B2 (en) * 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
CA2619889C (en) * 2005-08-22 2020-05-05 The Johns Hopkins University Use of itraconazole and salts thereof for treating cancer

Also Published As

Publication number Publication date
EP1411938B1 (de) 2005-07-06
AU2003230541A1 (en) 2003-11-03
US7605167B2 (en) 2009-10-20
MXPA04010294A (es) 2005-05-17
US20080090790A1 (en) 2008-04-17
US9757361B2 (en) 2017-09-12
KR20070108287A (ko) 2007-11-08
CA2481499C (en) 2013-05-21
EP1411938A1 (de) 2004-04-28
CN1835748A (zh) 2006-09-20
US20040072913A1 (en) 2004-04-15
AU2003230541B2 (en) 2006-06-29
KR20080094739A (ko) 2008-10-23
US20040072914A1 (en) 2004-04-15
DE60302348D1 (de) 2005-12-22
DK1496895T3 (da) 2006-03-27
CA2481499A1 (en) 2003-10-30
US8025893B2 (en) 2011-09-27
CN101642458A (zh) 2010-02-10
CA2636960C (en) 2013-12-31
US20110104254A1 (en) 2011-05-05
US20080089915A1 (en) 2008-04-17
JP2006512281A (ja) 2006-04-13
BR0309396A (pt) 2005-02-09
CA2636960A1 (en) 2003-10-30
ES2253672T3 (es) 2006-06-01
EP1496895B1 (de) 2005-11-16
KR20080096605A (ko) 2008-10-30
US20100048725A2 (en) 2010-02-25
WO2003088964A1 (en) 2003-10-30
KR20040102117A (ko) 2004-12-03
EA200401355A1 (ru) 2005-06-30
EP1496895A1 (de) 2005-01-19
DE60302348T2 (de) 2006-07-27
US20090286822A1 (en) 2009-11-19
US7893078B2 (en) 2011-02-22
CA2452152A1 (en) 2002-10-10
US7629352B2 (en) 2009-12-08

Similar Documents

Publication Publication Date Title
ATE309802T1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
WO2005030083A3 (en) Methods and products which utilize n-acyl-l-aspartic acid
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
DE50109320D1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1496895

Country of ref document: EP

REN Ceased due to non-payment of the annual fee